Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D₂/D₃ Selective Receptor Antagonist for the Management of Gastroparesis

References

• Koch KL, Stern RM, Stewart WR, Vasey MW. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment. Am J Gastroenterol. 1989;84(9):1069–1075.
   PubMed Web of Science ®Google Scholar
• Koch KL. Gastric dysrhythmias: a potential objective measure of nausea. Exp Brain Res. 2014;232(8):2553–2561. doi:10.1007/s00221-014-4007-9
   PubMed Web of Science ®Google Scholar
• Camilleri M, Chedid V, Ford AC, et al. Gastroparesis. Nat Rev Dis Primers. 2018;4(1):41. doi:10.1038/s41572-018-0038-z
   PubMed Web of Science ®Google Scholar
• Bekkelund M, Sangnes DA, Gunnar Hatlebakk J, Aabakken L. Pathophysiology of idiopathic gastroparesis and implications for therapy. Scand J Gastroenterol. 2019;54(1):8–17. doi:10.1080/00365521.2018.1558280
   PubMed Web of Science ®Google Scholar
• Gharibans AA, Coleman TP, Mousa H, Kunkel DC. Spatial patterns from high-resolution electrogastrography correlate with severity of symptoms in patients with functional dyspepsia and gastroparesis. Clin Gastroenterol Hepatol. 2019;17(13):2668–2677. doi:10.1016/j.cgh.2019.04.039
   PubMed Web of Science ®Google Scholar
• Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127(5):1592–1622.
   PubMed Web of Science ®Google Scholar
• Nassar Y, Richter S. Gastroparesis in non-diabetics: associated conditions and possible risk factors. Gastroenterol Res. 2018;11(5):340–345. doi:10.14740/gr1060w
   PubMed Web of Science ®Google Scholar
• Bharadwaj S, Meka K, Tandon P, et al. Management of gastroparesis‐associated malnutrition. J Dig Dis. 2016;17(5):285–294. doi:10.1111/1751-2980.12344
   PubMed Web of Science ®Google Scholar
• Grover M, Farrugia G, Stanghellini V. Gastroparesis: a turning point in understanding and treatment. Gut. 2019;68(12):2238–2250. doi:10.1136/gutjnl-2019-318712
   PubMed Web of Science ®Google Scholar
• Jung HK, Locke III GR, Schleck CD, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136(4):1225–1233. doi:10.1053/j.gastro.2008.12.047
   PubMed Web of Science ®Google Scholar
• Syed AR, Wolfe MM, Calles-Escandon J. Epidemiology and diagnosis of gastroparesis in the United States: a population-based study. J Clin Gastroenterol. 2020;54(1):50–54. doi:10.1097/MCG.0000000000001231
   PubMed Web of Science ®Google Scholar
• Moshiree B, Potter M, Talley NJ. Epidemiology and pathophysiology of gastroparesis. Gastrointestinal Endoscopy Clin. 2019;29(1):1–14. doi:10.1016/j.giec.2018.08.010
   PubMedGoogle Scholar
• Janssen P, Harris SM, Jones M, et al. The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol. 2013;108(9):1382–1391. doi:10.1038/ajg.2013.118
   PubMed Web of Science ®Google Scholar
• Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab. 2010;5(5):653–662. doi:10.1586/eem.10.41
   PubMedGoogle Scholar
• Darmani NA, Zhao W, Ahmad B. The role of D2 and D3 dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew). J Neural Transm. 1999;106(11–12):1045–1061. doi:10.1007/s007020050222
   PubMed Web of Science ®Google Scholar
• Kashyap P, Micci MA, Pasricha S, Pasricha PJ. The D2/D3 agonist PD128907 (R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin- 9-ol) inhibits stimulated pyloric relaxation and spontaneous gastric emptying. Dig Dis Sci. 2009;54(1):57–62. doi:10.1007/s10620-008-0335-6
   PubMed Web of Science ®Google Scholar
• Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F. Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther. 2004;19(4):379–390. doi:10.1111/j.1365-2036.2004.01867.x
   PubMed Web of Science ®Google Scholar
• Kashyap PC, Micci M-A, Pasricha PJ. The dopamine-3 receptor and gastric motility. Am J Gastroenterol. 2005;100(Suppl):S54. doi:10.14309/00000434-200509001-00094
   Web of Science ®Google Scholar
• Enweluzo C, Aziz F. Gastroparesis: a review of current and emerging treatment options. Clin Exp Gastroenterol. 2013;6:161–165. doi:10.2147/CEG.S50236
   PubMedGoogle Scholar
• Homko CJ, Duffy F, Friedenberg FK, Boden G, Parkman HP. Effect of dietary fat and food consistency on gastroparesis symptoms in patients with gastroparesis. Neurogastroenterol Motility. 2015;27(4):501–508. doi:10.1111/nmo.12519
   PubMed Web of Science ®Google Scholar
• Camilleri M. Treatment of Gastroparesis. Waltham, MA: Wolters Kluwer Health. Available from: https://www.uptodate.com/contents/treatment-of-gastroparesis/print. Accessed January 2020.
   Google Scholar
• Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11–19. doi:10.1111/j.1365-2036.2009.04189.x
   PubMed Web of Science ®Google Scholar
• Rumore MM. Cardiovascular adverse effects of metoclopramide: review of literature. Int J Case Rep Images. 2012;3(5):1–10. doi:10.5348/ijcri-2012-05-116-RA-1
   Google Scholar
• Acosta A, Camilleri M. Prokinetics in gastroparesis. Gastroenterol Clin North Am. 2015;44(1):97–111. doi:10.1016/j.gtc.2014.11.008
   PubMed Web of Science ®Google Scholar
• Al‐Saffar A, Lennernäs H, Hellström PM. Gastroparesis, metoclopramide, and tardive dyskinesia: risk revisited. Neurogastroenterol Motility. 2019;31(11):e13617. doi:10.1111/nmo.13617
   PubMedGoogle Scholar
• European Medicines Agency (EMA). European Medicines Agency recommends changes to the use of metoclopramide; 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Metoclopramide_31/WC500146610.pdf. Accessed January 2020.
   Google Scholar
• Michaud V, Turgeon J. Domperidone and sudden cardiac death: how much longer should we wait? J Cardiovasc Pharmacol. 2013;61(3):215–217. doi:10.1097/FJC.0b013e31827e2573
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Domperidone summary of product characteristics; 2017. Available from: https://www.medicines.org.uk/emc/product/556/smpc#POSOLOGY. Accessed January 2020.
   Google Scholar
• Rossi M, Giorgi G. Domperidone and long QT syndrome. Curr Drug Saf. 2010;5(3):257–262. doi:10.2174/157488610791698334
   PubMedGoogle Scholar
• Leelakanok N, Holcombe A, Schweizer ML. Domperidone and risk of ventricular arrhythmia and cardiac death: a systematic review and meta-analysis. Clin Drug Investig. 2016;36(2):97–107. doi:10.1007/s40261-015-0360-0
   PubMed Web of Science ®Google Scholar
• Hellström PM, Al-Saffar A. Gastroparesis: pharmacotherapy and cardiac risk. Scand J Gastroenterol. 2018;53(5):513–518. doi:10.1080/00365521.2017.1401117
   PubMed Web of Science ®Google Scholar
• Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo‐controlled, double‐blind, crossover study. Br J Clin Pharmacol. 2012;73(3):411–421. doi:10.1111/j.1365-2125.2011.04093.x
   PubMed Web of Science ®Google Scholar
• Biewenga J, Keung C, Solanki B, et al. Absence of QTc prolongation with domperidone: a randomized, double‐blind, placebo‐and positive‐controlled thorough QT/QTc study in healthy volunteers. Clin Pharmacol Drug Develop. 2015;4(1):41–48. doi:10.1002/cpdd.126
   PubMed Web of Science ®Google Scholar
• Jolas T. In Vitro Pharmacology Study of ATC-1906M and ATC-9984. Eurofins Cerep: Cerep study number 100009687. 2013
   Google Scholar
• Whiting R, Choppin A, Luehr G, Jasper JR. Su1764 TAK-906, a novel dopamine D2/D3 receptor antagonist for the treatment of gastroparesis. Gastroenterology. 2020;158(6):S638–S639. doi:10.1016/S0016-5085(20)32292-7
   PubMed Web of Science ®Google Scholar
• Eurofins Cerep: Cerep Study Number 100018069.
   Google Scholar
• Eurofins Cerep: Cerep Study Number 100019379.
   Google Scholar
• Whiting RL, Darpo B, Chen C, et al. Safety, pharmacokinetics, and pharmacodynamics of trazpiroben (TAK‐906, a novel selective D2/D3D2/D3 receptor antagonist: a Phase 1 randomized, placebo-controlled single- and multiple-dose escalation study in healthy participants. Clin Pharmacol Drug Develop. 2021;10(8):927–939. doi:10.1002/cpdd.906
   PubMed Web of Science ®Google Scholar
• Williams S. Covance Laboratories Inc.. Covance Study Number 8294200. Escalating Repeat-Dose Range-Finding Toxicity Study with ATC-1906 (Maleate Salt) in Rats. 2014.
   Google Scholar
• Covance Laboratories Inc.. Covance Study Number 8294202. Escalating-Dose Range-Finding Study (Phase I) and 7-Day Repeat-Dose Toxicity and Toxicokinetics (Phase II) Oral Capsule Study with ATC-1906 (Maleate Salt) in Dogs.
   Google Scholar
• Williams S. Covance Laboratories Inc.. Covance Study Number 8294203. A 4-Week Oral Capsule Toxicity and Toxicokinetic Study of ATC-1906 (Maleate Salt) in Dogs with a 2-Week Recovery Phase. 2014.
   Google Scholar
• King A, Bailie M, Olivier NB. Magnitude of error introduced by application of heart rate correction formulas to the canine QT interval. Ann Noninvasive Electrocardiol. 2006;11(4):289–298. doi:10.1111/j.1542-474X.2006.00120.x
   PubMed Web of Science ®Google Scholar
• Winer BJ, Brown DR, Michels KM. Analysis of covariance. In: Statistical Principles in Experimental Design. 3rd ed. New York: McGraw–Hill. 1991a; (Chapter 10): 739–836.
   Google Scholar
• Winer BJ, Brown DR, Michels KM. Single-factor experiments having repeated measures on the same elements. In: Statistical Principles in Experimental Design. 3rd ed. New York: McGraw–Hill. 1991b; (Chapter 4): 220–281.
   Google Scholar
• Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc. 1955;50(272):1096–1121. doi:10.1080/01621459.1955.10501294
   Web of Science ®Google Scholar
• Dunnett CW. New tables for multiple comparisons with a control. Biometrics. 1964;20(3):482–491. doi:10.2307/2528490
   Web of Science ®Google Scholar
• Hsu JC. Multiple Comparisons: Theory and Methods. London, England: Chapman & Hall; 1996.
   Google Scholar
• Dinkel V, Harris D. Covance Laboratories Inc.. Covance Study Number 8320963. Concentrations of Prolactin in Serum and of ATC-1906 in Plasma and CSF Levels After Multiple Oral Doses of ATC-1906M to Rats. 2015.
   Google Scholar
• Dinkel V, Harris D. Covance Laboratories Inc.. Covance Study Number 8320964. Concentrations of Prolactin in Serum and of ATC-1906 in Plasma and CSF Levels After Multiple Oral Doses of ATC-1906M to Dogs. 2015.
   Google Scholar
• Rankovic Z. CNS drug design: balancing physicochemical properties for optimal brain exposure. J Med Chem. 2015;58(6):2584–2608. doi:10.1021/jm501535r
   PubMed Web of Science ®Google Scholar
• Jasper J, Whiting R. TAK-906, a dopamine D2/D3 receptor antagonist with minimal brain penetration for gastrointestinal disorders. J Fed Am Soc Exp Biol. 2020;34(Suppl):1. doi:10.1096/fasebj.2020.34.s1.09414
   Web of Science ®Google Scholar
• Hansch C, Björkroth JP, Leo A. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J Pharm Sci. 1987;76(9):663–687. doi:10.1002/jps.2600760902
   PubMed Web of Science ®Google Scholar
• Pitrè D, Stradi R. Metoclopramide hydrochloride. Anal Profiles Drug Substances. 1987;16:327–360.
   Google Scholar
• Jolliet P, Nion S, Allain-Veyrac G, et al. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood–brain barrier. Pharmacol Res. 2007;56(1):11–17. doi:10.1016/j.phrs.2006.12.004
   PubMed Web of Science ®Google Scholar
• Tournier N, Bauer M, Pichler V, et al. Impact of P-glycoprotein function on the brain kinetics of the weak substrate 11C-metoclopramide assessed with PET imaging in humans. J Nucl Med. 2019;60(7):985–991. doi:10.2967/jnumed.118.219972
   PubMed Web of Science ®Google Scholar
• Burton C, Krueger M. Covance Laboratories Inc.. Covance Study Number 8328073. Determination of Prolactin Levels After a Single Oral Dose of ATC-1906M or Domperidone to Rats. 2015.
   Google Scholar
• Whiting R. Covance Laboratories Inc.. Covance Study Number 8335390. A Phase 1, Adaptive-Design, First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, Food Effect, and Pharmacodynamics of ATC-1906M Capsules in Healthy Volunteers. 2016.
   Google Scholar
• Kuo B, Scimia C, Dukes G, et al. Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2/D3 receptor antagonist, in patients with gastroparesis. Aliment Pharmacol Ther. 2021;54(3):267–280. doi:10.1111/apt.16451
   PubMed Web of Science ®Google Scholar
• ChanTest: Study number 131015.BMX. Effect of TAK-906 on Cloned hERG Potassium Channels Expressed in Human Embryonic Kidney Cells.
   Google Scholar
• Claassen S, Zünkler BJ. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005;74(1):31–36. doi:10.1159/000083234
   PubMed Web of Science ®Google Scholar
• Doggrell SA, Hancox JC. Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine. Expert Opin Drug Saf. 2014;13(1):131–138. doi:10.1517/14740338.2014.851193
   PubMed Web of Science ®Google Scholar